Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neurofibromatosis 1 12Neurofibroma, Plexiform 6Carcinoma, Non-Small-Cell Lung 4Neurofibrosarcoma 3Neoplasms 3Lung Neoplasms 3Melanoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Doxorubicin 26pembrolizumab 24Radiotherapy 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17Specimen Handling 14Nivolumab 14Gemcitabine 13Ifosfamide 12Surgical Procedures, Operative 11Biopsy 11Radiation 10X-Rays 8Temozolomide 8Ipilimumab 8pazopanib 7fludarabine 7cabozantinib 7Irinotecan 7tazemetostat 6liposomal doxorubicin 6Trabectedin 6Surveys and Questionnaires 6Phantoms, Imaging 6Blood Specimen Collection 6olaparib 5eribulin 5atezolizumab 5anlotinib 5Vincristine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × AZD 6244 × 1 year × Clear all
NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡